SCHEMBL4992909

SCHEMBL4992909

COc1ccc(OC(=O)c2ccc([N+](=O)[O-])cc2)c(C(C)=O)c1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.69
KMT2A Q03164 5/20 0.69
ALDH1A1 P00352 5/20 0.57
LMNA P02545 2/20 0.57
HTT P42858 2/20 0.56
RECQL P46063 1/20 0.56
MAPK1 P28482 3/20 0.54
KDM4E B2RXH2 1/20 0.54
POLB P06746 1/20 0.54
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
PKM P14618 1/20 0.51
KLK7 P49862 1/20 0.50
NR1H4 Q96RI1 1/20 0.49
GAA P10253 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MAOB P27338 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25326319 0.87 KMT2A (0.84) MAPTKMT2AALDH1A1HTTMAPK1
SCHEMBL4985532 0.85 MAPT (0.54) MAPTKMT2AALDH1A1HTTMAPK1
SCHEMBL10144241 0.84 MAPK1 (0.49) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL7344334 0.81 MAPK1 (0.64) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL4982840 0.80 MAPT (0.57) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL4982850 0.80 MAPT (0.57) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL24492673 0.80 KMT2A (0.66) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL5345292 0.80 KMT2A (0.72) MAPTKMT2AALDH1A1LMNAHTT
SCHEMBL14451787 0.79 KMT2A (0.50) MAPTKMT2AALDH1A1LMNAMAPK1
SCHEMBL17301248 0.78 KMT2A (0.70) MAPTKMT2AHTTMAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8192717-B2 Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening NAGASAKI UNIVERSITY (JP) 2012-06-05 US disclosed
US-8192717-B2 Flavone derivative, chalcone derivative, styrylchromone derivative, or a coumarin derivative with high binding specificity to an amyloid beta protein, high permeability to a blood-brain barrier, and ability to rapidly disappear from sites other than cerebral senile plaque; also drug screening NAGASAKI UNIVERSITY (JP) 2012-06-05 US disclosed
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases Mori, Hiroshi (JP) 2008-06-05 US disclosed
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases Mori, Hiroshi (JP) 2008-06-05 US disclosed
EP-1815872-A1 COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS Nagasaki University (JP) 2007-08-08 EP disclosed
EP-1815872-A1 COMPOSITION FOR AMYLOID-ASSOCIATED DISEASE DIAGNOSIS Nagasaki University (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080131367-A1 Composition For Diagnosing Amyloid-Related Diseases APP, APBA1, FABP7 MAPT 20/4885KMT2A 4676/4885ALDH1A1 3190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.